Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director


Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director

PR Newswire

PHILADELPHIA, Aug. 13, 2014 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015. Separately, Tarsa announced that Daniel Soland has been appointed to the company's Board of Directors.

"As we prepare to file the NDA for our oral recombinant calcitonin tablet, we are pleased to have the support of these two respected financial institutions who have a great deal of experience in the life sciences and venture communities," noted David Brand, President and CEO of Tarsa. "We believe Ostora may be an attractive therapeutic option for many of the millions of women with osteoporosis who cannot or will not take other therapies. Our oral calcitonin is well-tolerated and has been shown to have a positive effect on bone mineral density at the lumbar spine. Our research suggests that many women would welcome the option of calcitonin in a once-daily oral formulation."

In a Phase III global, randomized, double-blind clinical study in postmenopausal women with osteoporosis known as the ORACAL trial, Tarsa's once-daily oral calcitonin demonstrated superiority to both placebo and commercially-available nasal calcitonin spray in increasing bone mineral density at the lumbar spine after 48 weeks. In the trial, the safety profile of Tarsa's oral calcitonin did not substantially differ from nasal calcitonin or placebo. The trial results were published in the Journal of Bone and Mineral Research .

Daniel Soland was Vice President and Chief Operating Officer of Viropharma until its acquisition by Shire early in 2014. He helped build the organizational and commercial infrastructure that resulted in an 11-fold increase in Viropharma's share price during his tenure. Previously, as President of Chiron Vaccines, Mr. Soland helped engineer a turnaround that contributed to Chiron's acquisition by Novartis. Earlier, he was President and CEO of Epigenesis Pharmaceuticals. At GlaxoSmithKline Biologicals, Mr. Soland served as Vice President and Director, Worldwide Marketing Operations. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux's Connaught Laboratories. He holds a BS in Pharmacy degree from the University of Iowa.

Tarsa's Chairman, Eric Bednarski, commented, "Dan Soland brings to Tarsa a diverse set of operating and sales and marketing experiences and he has led fast growing, profitable commercial organizations. We are delighted to have him join our board as we finalize the NDA for Ostora and prepare to commercialize this important new osteoporosis therapy."

About Tarsa Therapeutics
Tarsa is developing Ostora, a novel oral formulation of calcitonin for the treatment of postmenopausal osteoporosis in women greater than five years post menopause when alternative treatments are not suitable. This product has the potential to be the first approved oral calcitonin, a natural hormone with a long history of safety and efficacy as a treatment for osteoporosis. Tarsa is based in Philadelphia, PA. For more information, visit www.tarsatherapeutics.com.

About Oxford Finance LLC
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $2 billion in loans, with lines of credit ranging from $500 thousand to $75 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Illinois, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.

About Square 1 Bank
Square 1 Bank is a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion. Square 1's expertise, focus and strong capital base provide flexible resources and unmatched support to meet our clients' needs. Square 1 has offices coast-to-coast in Austin, the Bay Area, Boston, Denver, Durham, Los Angeles/Orange County, New York, San Diego, Seattle, Silicon Valley and Washington, DC. For more information, visit www.square1bank.com.

Contact:
BLL Partners, LLC
Barbara Lindheim
212 584-2276
blindheim@bllbiopartners.com

SOURCE Tarsa Therapeutics

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here